1 / 7

Group Work 1

Group Work 1. Q uality Assurance Programmes Report from Group A Dr Prem Sanjeev Singh. Group Work 1. Current WHO EQAP for detection of influenza A by PCR. Strengths? Routine feedback Monitors the maintenace of quality and standards Recognizes capactiy Weaknesses?

infinity
Download Presentation

Group Work 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Group Work 1 Quality Assurance Programmes Report from Group A Dr Prem Sanjeev Singh

  2. Group Work 1

  3. Current WHO EQAP for detection of influenza A by PCR Strengths? • Routine feedback • Monitors the maintenace of quality and standards • Recognizes capactiy Weaknesses? • Not mandatory – laboratories can opt out Areas to improve? • Adjust frequency of testing based on previous results

  4. Other programmes: do you participate in the following? List the labs participating in the following programmes • No for influenza PCR for the Group A countries Fee-paying: • QCMD: Quality Control Molecular Diagnostics, operated by the EU • NEQAS: National External Quality Assessment Scheme, from the UK • CAP: College of American Pathologists, from the US Free: • U. S. CDC Strengths and Weaknesses of the above programmes: no information

  5. Scope of EQAP: Needs to be expanded? If an NIC performs the test routinely and is not required to have the test confirmed by an Collaborating Center, then there should an EQAP> • Virus culture • Antivirals (phenotypic or genotypic) • Sequencing • Serology • Others • Which labs/NICs are doing each of the above? • What methods? • If currently not doing, any plan in the mid-term or long term? • Priority of launching programme?

  6. Scope of EQAP: Needs to be expanded? • Which labs/NICs are doing the above tests? • China, Hong Kong (SAR), Japan • Fiji is not • Which tests? • All three of them • If not doing, any plan to do? • Fiji: plan to do viral cultural in the mid-term; this is a high priority

  7. Preferred features of EQAP? • Number of samples: ten (status quo) • Type of samples: inactivate virus (status quo) for viral cultural, use lyophilized cultures • Frequency : see above: determined by past performance • Time to reporting: one month (status quo) minority view: if treated as a clinical sample, should be shorter • Format of reports: should be simplified • Others

More Related